Company Monitoring Page for Regeneron

job ratings (see below graph) for Regeneron

latest headlines for company on cafepharma

3 Reasons Regeneron Stock Could Start Climbing Again
Yahoo/Motley Fool
Sun, 05/6/18 - 01:14 pm
Tags:
Sanofi, Regeneron, Praluent, Dupixent, Eylea
Regeneron halts high doses of phase 3 osteoarthritis drug fasinumab amid risk-benefit concerns
Fierce Biotech
Fri, 05/4/18 - 10:05 am
Tags:
Regeneron, fasinumab, clinical trials, osteoarthritis
Regeneron (REGN) Q1 Earnings Top, Sales Lag, Updates View
Yahoo/Zacks.com
Thu, 05/3/18 - 11:18 am
Tags:
Regeneron, earnings
Express Scripts Picks Regeneron Over Amgen, Cuts Heart Drug Price
Xconomy
Tue, 05/1/18 - 09:59 am
Tags:
Regeneron, Sanofi, Express Scripts, PBMs, Praluent, drug pricing
Eyeing Eylea’s $5B sales, Novartis touts solid 12-week dosing data for its rival RTH258
Endpoints
Mon, 04/30/18 - 09:04 pm
Tags:
Novartis, Regeneron, Eylea, RTH258, wet age-related macular degeneration
Regeneron/Sanofi circle October 28 on the calendar as the FDA begins a speedy review of the world’s 6th PD-1/L1 checkpoint
Endpoints
Mon, 04/30/18 - 10:08 am
Tags:
Regeneron, Sanofi, PD-1 inhibitors, FDA, cemiplimab
Biotech stars Schleifer and Yancopoulos share $52M in 2017 compensation, even though Regeneron’s share price swooned
Endpoints
Tue, 04/24/18 - 10:10 am
Tags:
Regeneron, Len Schleifer, George Yancopoulos, Pharma CEOs, executive pay
Novartis sues Regeneron over manufacturing methods
Biopharma Dive
Thu, 03/29/18 - 09:14 pm
Tags:
Novartis, Regeneron, drug manufacturing, Zaltrap, Eylea
Regeneron, Alnylam partner to turn discovery into new drugs for NASH
Biopharma Dive
Thu, 03/22/18 - 10:26 pm
Tags:
Regeneron, Alnylam, NASH, R&D, drug discovery
Regeneron’s Eylea Shows Promise in Late-Stage Diabetic Retinopathy Trial
Xtalks
Tue, 03/20/18 - 09:45 am
Tags:
Regeneron, Eylea, diabetic retinopathy
With Novartis and Roche gunning to carve up Eylea franchise, Regeneron has another PhIII success story to tell
Endpoints
Mon, 03/19/18 - 11:44 am
Tags:
Novartis, Roche, Eylea, Regeneron
Amgen faces tough one-two blow as competition mounts for Repatha and Sensipar
Fierce Pharma
Tue, 03/13/18 - 09:30 pm
Tags:
Amgen, Repatha, Sensipar, generics, Sanofi, Regeneron, Praluent
Regeneron/Sanofi heart drug succeeds in major trial; Will insurers pay?
Yahoo/Reuters
Sun, 03/11/18 - 11:50 am
Tags:
Regeneron, Sanofi, Praluent, insurers, clinical trials
Regeneron to Slash Price of Cholesterol Drug After Showing it Saved Lives
Xconomy
Sat, 03/10/18 - 09:12 am
Tags:
Regeneron, cholesterol, drug pricing, Sanofi, Praluent
Here's What Weighed on Regeneron Pharmaceuticals Inc. in February
Motley Fool
Wed, 03/7/18 - 09:22 am
Tags:
Regeneron, Eylea
Regeneron vision drug Eylea sees upward tick in unexplained side-effect cases
Fierce Pharma
Thu, 02/22/18 - 11:14 pm
Tags:
Regeneron, Eylea, side effects
The Moment Of Truth Is Coming For Struggling And Expensive Cholesterol Drugs
Forbes
Sun, 02/18/18 - 10:16 am
Tags:
cholesterol, PCSK9 inhibitors, Sanofi, Regeneron, Praluent, Amgen, Repatha
Regeneron’s coming late to a group of drugs that’s already worth billions — here’s why the company thinks it can still compete
SF Gate, CA
Sat, 02/10/18 - 09:47 am
Tags:
Regeneron, PDL-1 inhibitors, cemiplimab
Racing to replace opioids, biopharma is betting on pain drugs with a checkered past
Stat
Wed, 01/31/18 - 11:00 am
Tags:
opioids, painkillers, NGF inhibitors, Regeneron, Pfizer, Eli Lilly, NGF blockers
Sanofi and Regeneron's Dupixent launch is about to get a cash infusion
Fierce Pharma
Wed, 01/10/18 - 10:07 am
Tags:
Sanofi, Regeneron, Dupixent, drug launches, eczema, JPMHC 2018

Pages

last 30 twitter posts

current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.